-
FDA Approves Imetelstat for Myelodysplastic Syndromes with Transfusion-Dependent Anemia
On June 6, the US Food and Drug Administration (FDA) approved imetelstat, an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia—requiring 4 or more red blood cell units over 8 weeks—who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents.
For more information read the FDA announcement and the Geron announcement.
Posted 6/7/2024
-
FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Mantle Cell Lymphoma
On May 30, the US Food and Drug Administration (FDA) approved lisocabtagene maraleucel for adult patients with relapsed or refractory mantle cell lymphoma who have received at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor.
For more information read the FDA announcement and the Bristol Meyers Squibb announcement.
Posted 6/4/2024
-
FDA Approves Tarlatamab-dlle for Extensive-Stage Small Cell Lung Cancer
On May 16, the US Food and Drug Administration granted accelerated approval to tarlatamab-dlle for extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.
For more information read the FDA announcement and the Amgen Inc. announcement.
Posted 5/20/2024
-
FDA Approves Lisocabtagene Maraleucel for Follicular Lymphoma
On May 15, the US Food and Drug Administration (FDA) granted accelerated approval to lisocabtagene maraleucel for adults with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
For more information read the FDA announcement.
Posted 5/16/2024
-
FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer
On April 29, the US Food and Drug Administration (FDA) granted traditional approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tisotumab vedotin-tftv previously received accelerated approval for this indication.
For more information read the FDA announcement and the Pfizer announcement.
Posted 4/30/2024
-
FDA Approves Lutetium Lu 177 Dotatate for Pediatric Patients with Astroenteropancreatic Neuroendocrine Tumors
On April 23, the US Food and Drug Administration (FDA) approved lutetium Lu 177 dotatate for pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors.
For more information read the FDA announcement.
Posted 4/24/2024
-
FDA Approves Nogapendekin Alfa Inbakicept-pmln for Invasive Bladder Cancer
On April 22, the US Food and Drug Administration approved nogapendekin alfa inbakicept-pmln in combination with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.
For more information read the FDA announcement.
Posted 4/23/2024
-
FDA Approves Alectinib for ALK-positive Non-Small Cell Lung Cancer
On April 18, the US Food and Drug Administration (FDA) approved alectinib for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer, as detected by an FDA-approved test.
For more information read the FDA announcement and the Genentech Inc. announcement.
Posted 4/18/2024
-
FDA Approves Idecabtagene vicleucel for Relapsed or Refractory Multiple Myeloma
On April 4, the US Food and Drug Administration (FDA) approved idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma after 2 or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
For more information read the Bristol Myers Squibb announcement.
Posted 4/9/2024
-
FDA Approves Fam-trastuzumab deruxtecan-nxki for Unresectable or Metastatic HER2-positive Solid Tumors
On April 5, the US Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.
For more information read the FDA announcement.
Posted 4/8/2024